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OBJECTIVE—To quantitate plasma ceramide subspecies con-
centrations in obese subjects with type 2 diabetes and relate
these plasma levels to the severity of insulin resistance. Cer-
amides are a putative mediator of insulin resistance and lipotox-
icity, and accumulation of ceramides within tissues in obese and
diabetic subjects has been well described.
RESEARCH DESIGN AND METHODS—We analyzed fasting
plasma ceramide subspecies by quantitative tandem mass spec-
trometry in 13 obese type 2 diabetic patients and 14 lean healthy
control subjects. Results were related to insulin sensitivity
measured with the hyperinsulinemic-euglycemic clamp tech-
nique and with plasma tumor necrosis factor- (TNF-) levels, a
marker of inﬂammation. Ceramide species (C18:1, 18:0, 20:0,
24:1, and 24:0) were quantiﬁed using electrospray ionization
tandem mass spectrometry after separation with high-perfor-
mance liquid chromatography.
RESULTS—Insulin sensitivity (mg  kg
1  min
1) was lower in
type 2 diabetic patients (4.90  0.3) versus control subjects
(9.6  0.4) (P  0.0001). Type 2 diabetic subjects had higher (P 
0.05) concentrations of C18:0, C20:0, C24:1, and total ceramide.
Insulin sensitivity was inversely correlated with C18:0, C20:0,
C24:1, C24:0, and total ceramide (all P  0.01). Plasma TNF-
concentration was increased (P  0.05) in type 2 diabetic
subjects and correlated with increased C18:1 and C18:0 ceramide
subspecies.
CONCLUSIONS—Plasma ceramide levels are elevated in type 2
diabetic subjects and may contribute to insulin resistance
through activation of inﬂammatory mediators, such as TNF-.
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T
ype 2 diabetes is an insulin-resistant state char-
acterized by impaired glucose tolerance (1) and
inﬂammation (2). Much evidence has demon-
strated the role of increased circulating free fatty
acids and tissue fat accumulation in the development of
muscle and liver insulin resistance (1,3,4). The distur-
bances in plasma and tissue lipid metabolism result from
an oversupply of lipid substrates, both exogenously and
endogenously (increased lipolysis secondary to adipocyte
insulin resistance), and perturbations in fat oxidation and
utilization by muscle and liver, resulting in the accumula-
tion of ectopic fat (4). Ectopic fat is “lipotoxic” and has
been linked to the severity of insulin resistance and
pancreatic -cell dysfunction, i.e., the core defects in type
2 diabetes (1,4). Ectopic fat comprises various lipid spe-
cies, including long-chain fatty acyl CoAs, diacylglycerol, and
ceramide. It is well documented that ceramide accumulates
within insulin-resistant tissues of animals (5–7) and humans
(8–10) and inhibits insulin action and subsequent glucose
uptake through inactivation of Akt. Ceramide also induces
inﬂammation through activation of the nuclear factor-B–
tumor necrosis factor- (TNF-) axis (5–7).
TNF- is released from adipocytes and circulating
mononuclear cells (MNCs) in response to stimuli, such as
lipid infusion, lipopolysaccharide, reactive oxygen spe-
cies, and hyperglycemia, and elevated TNF- concentra-
tions have been shown to induce insulin resistance (11–
14). TNF- also activates the plasma membrane enzyme
sphingomyelinase (SMase) that hydrolyzes sphingomyelin
to ceramide, allowing ceramides to accumulate within the
cell (5,6,15–17). This accumulation of ceramide within
tissues is thought to initiate a positive feedback mechanism,
leading to enhanced production of proinﬂammatory cyto-
kines (5), resulting in further inhibition of insulin-stimulated
glucose uptake. Both plasma TNF- concentrations and
intracellular lipid intermediates, such as ceramides, are ele-
vated in subjects with type 2 diabetes (8,18). Thus, ceramide
is a bioactive lipid and putative mediator of insulin resistance
that could link nutrient (fat) oversupply and cytokine-
induced inﬂammation in tissues (5–7).
Plasma ceramide levels also have been shown to correlate
with coronary artery disease, independent of the plasma
cholesterol concentration (19,20). However, the role of cir-
culating ceramides has received little attention with respect
to the development of insulin resistance and type 2 diabetes.
Conﬂicting reports exist as to whether total circulating
ceramides are elevated in obese (21) and type 2 diabetic
subjects (22). Subspecies of plasma ceramides have been
demonstrated to be increased in patients with sepsis and
atherosclerosis (23–25), but the relationship between plasma
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been investigated in patients with type 2 diabetes.
Given their central role in the induction of insulin resis-
tance and inﬂammation, elevated plasma ceramide levels
may serve as a biomarker or direct perpetuator of insulin
resistance and lipid-induced inﬂammation. Elevated plasma
ceramide concentrations also may serve to identify individ-
uals who are at risk to develop type 2 diabetes. The objective
of this study was to quantify the concentration of individual
ceramide subspecies in the circulation of patients with type
2 diabetes and healthy control subjects and to examine the
correlation between plasma levels of ceramide subspecies
and insulin sensitivity, measured with the euglycemic-hyper-
insulinemic clamp, and plasma TNF- concentration, a
marker of inﬂammation.
RESEARCH DESIGN AND METHODS
Twenty-seven subjects were recruited from the greater San Antonio metro-
politan area. Thirteen subjects had type 2 diabetes, and 14 were healthy
nondiabetic control subjects. Descriptive data from these subjects has been
presented in previous reports (26,27) (Table 1). Type 2 diabetic subjects were
older and more obese than nondiabetic subjects and were characterized by
dyslipidemia and hyperglycemia (Table 1). Normal glucose tolerance was
conﬁrmed in all control subjects by a 75-g oral glucose tolerance test using
American Diabetes Association criteria (28). After a 10- to 12-h overnight fast,
body composition was assessed with bioelectrical impedance in all subjects
(29). Type 2 diabetic subjects were in reasonably good glycemic control, as
reﬂected by a mean A1C of 7.5%. Type 2 diabetic patients were treated with
diet (n  8) or sulfonylureas (n  5). No type 2 diabetic subject had received
treatment with metformin, thiazolidinediones, or insulin. The mean duration
of diabetes was 5 years. Five type 2 diabetic subjects had normal fasting
plasma glucose concentrations and were diagnosed with an oral glucose
tolerance test (2-h plasma glucose 200 mg/dl). Oral antidiabetic agents were
discontinued 24 h before the study. Other than diabetes, none of the subjects
had any medical problems, and none were taking any medications (other than
sulfonylureas) known to affect glucose metabolism. None of the participants
smoked, and none of the women were on hormone replacement therapy.
Weight was stable (3 lb) in all subjects for the 3 months before study, and
no subject participated in an excessively heavy exercise program. The
purpose, nature, and potential risks of the study were explained to all
subjects, and written consent was obtained before their participation. The
protocol was approved by the Institutional Review Board of the University of
Texas Health Science Center at San Antonio.
All studies were conducted in the General Clinical Research Center of the
University of Texas Health Science Center at San Antonio and began at 0700 h
after a 12-h overnight fast. Before the start of the euglycemic insulin clamp
study, an anticubital vein was cannulated for infusion of all test substances. A
second catheter was inserted retrogradely into a dorsal hand vein, and the
hand was placed in a heated box (60°C) to obtain arterialized blood samples.
A primed (25 Ci 	 fasting plasma glucose/100)-continuous infusion (0.25
Ci/min) of 3-[
3H]glucose was started2h( 3hf o rtype 2 diabetes) before the
start of the insulin clamp to allow for isotopic equilibration. The priming dose
of tritiated glucose was increased in the type 2 diabetic subjects in proportion
to the increase in their fasting plasma glucose concentration. At the end of the
tracer equilibration period, blood was obtained for determination of plasma
ceramide and TNF- levels. At time 0, a primed-continuous infusion (80 mU 
m
2  min
1) of insulin was started and continued for 4 h. During insulin
infusion, the plasma glucose concentration was measured every 5 min with a
Glucose Oxidase Analyzer (Beckman Instruments, Fullerton, CA). Based on
the negative-feedback principle, a variable infusion of 20% glucose was
adjusted to maintain the plasma glucose concentration constant at each
subject’s fasting plasma glucose level in the control group. In type 2 diabetic
subjects, the plasma glucose concentration was allowed to decrease during
the insulin infusion to 100 mg/dl, at which level it was maintained.
Analytical determinations. Plasma tritiated glucose speciﬁc activity was
determined using barium hydroxide/zinc sulfate extracts of plasma. Plasma
insulin concentration was determined by radioimmunoassay (Diagnostic
Products, Los Angeles, CA). Plasma free fatty acid concentration was deter-
mined by colorimetric assay (Wako, Neuss, Germany). Plasma TNF- concen-
tration was determined by UltraSensitive ELISA (Biosource International,
Camarillo, CA).
Ceramide subspecies analysis
Sample preparation. Calibration curves (0–1,000 ng) for each ceramide
standard (purity 
99%; Avanti Polar Lipids, Alabaster, AL) were prepared in
100 l plasma matrix. C17:0 ceramide was used as a nonnaturally occurring
internal standard. Plasma samples (100 l), in parallel with standard solutions,
were spiked with 100 ng C17:0 ceramide and were extracted with 2 ml
chloroform:methanol (1:2) mixture according to the protocol of Bligh and
Dyer (30). Phases were broken by adding 0.5 ml chloroform and 0.5 ml water.
The lower organic fraction was removed, and the remainder was extracted
with an additional 1 ml chloroform. The pooled organic phase was dried under
nitrogen gas, and the residue was reconstituted in 500 l methylene chloride
and loaded onto a silica gel column packed with 2 ml silica gel suspension in
methylene chloride. Columns were washed with 1 ml methylene chloride, and
ceramides were eluted with 2 	 2 ml 30% isopropanol in methylene chloride.
Eluent was dried under nitrogen gas and the residue was reconstituted in
high-performance liquid chromatography (HPLC) elution buffer and analyzed
by mass spectrometry.
Mass spectrometry. Ceramide species were quantiﬁed by HPLC on-line
electrospray ionization tandem mass spectrometry (MS/MS). For optimiza-
tion, the mixture of ceramide standards was infused directly into the mass
spectrometer, and all source parameters and ionization conditions were
adjusted to improve the sensitivity of the assay. Extracted samples (40 l)
were injected onto a Waters HPLC (2690 Separations Module; Waters,
Franklin, MA) and separated through an Ascentis C18 column (2.1 	 50 mm,
5 m; SUPELCO, Bellefonte, PA) using a gradient starting from 15% mobile
phase A (water containing 0.2% formic acid) at a ﬂow rate of 0.3 ml/min for 1
min, to 100% mobile phase B (methanol containing 0.2% formic acid) over 3
min, and then with 100% B for 22 min. The HPLC column efﬂuent was
introduced onto a Micromass triple quadruple mass spectrometer (Quattro
Ultima; Waters) and analyzed using electrospray ionization in positive mode.
A potential difference of 3 keV was applied between the electrospray needle
and the interior of the ion source. Hot nitrogen gas (250°C) was used to help
evaporate the solvent from the charged droplets and argon was used as the
collision gas. All ceramides were quantiﬁed using multiple reaction monitor-
ing. The MS/MS transitions (m/z) were 5523264 for C17:0, 5643264 for C18:1,
5663264 for C18:0, 5943264 for C20:0, 6483264 for C24:1, and 6503264 for
C24:0. Ceramide subspecies were quantiﬁed (nmol/ml) by taking the ratios of
the integrated peak areas (MassLynx 3.5; Manchester, U.K.) for each subspe-
cies to the area of C17:0. Total ceramide was calculated from the sum of C18:1,
C18:0, C20:0, C24:1, and C24:0 ceramide subspecies.
Calculations. During the postabsorptive period, the rate of glucose appear-
ance equals the rate of glucose disappearance and was calculated as the
tritiated glucose infusion rate (dpm/min) divided by the plasma tritiated
glucose speciﬁc activity (dpm/mg). During the euglycemic insulin clamp,
non–steady-state conditions prevail, and the rate of glucose appearance was
calculated with Steele’s non–steady-state equation, using a glucose distribu-
tion volume of 0.65. The rate of endogenous (primarily hepatic) glucose
production during the insulin clamp was calculated by subtracting the
exogenous glucose infusion rate from the tracer-derived rate of glucose
appearance. The rate of total body (primarily reﬂects muscle) insulin-
stimulated glucose disposal was calculated by adding the rate of residual
hepatic glucose production to the cold glucose infusion rate. The basal hepatic
insulin resistance index (IRI) was calculated as the product of basal hepatic
glucose production and the fasting plasma insulin concentration (31).
TABLE 1
Subject characteristics
Control
subjects
Type 2 diabetic
patients P value
n 14 13 —
Sex 9 men/5 women 6 men/7 women —
Age (years) 40  45 0  3 0.04
BMI (kg/m
2) 26.3  1 32.9  1 0.01
LBM (%) 72  26 4  2 0.01
FPG (mg/dl) 91  2 151  17 0.01
FPI (U/ml) 5.6  0.6 14.0  1.4 0.01
F-FFA (mol/l) 495  48 887  77 0.01
TG (mg/dl) 86  12 188  23 0.01
Total cholesterol
(mg/dl) 159  8 204  10 0.01
HDL (mg/dl) 47  34 5  2N S
LDL (mg/dl) 98  6 119  8N S
Data are means  SE. FPG, fasting plasma glucose; FPI, fasting
plasma insulin; F-FFA, fasting plasma free fatty acids; LBM, lean
body mass; TG, triglycerides.
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between groups for the ceramide species was performed using the Mann-
Whitney U test, and correlations were performed using Spearman’s rank
correlation coefﬁcient. For all other comparisons, a two-sample t test was
performed. In all tests, P  0.05 was considered signiﬁcant. For overall P value
comparison, parametric versus nonparametric tests were consistent with
means. All statistical analyses were performed using StatView version 5.0.1
(SAS Institute).
RESULTS
Metabolic characteristics. Type 2 diabetic subjects
were older, had a higher BMI, and increased fasting
plasma glucose, insulin, triglyceride, total cholesterol, and
free fatty acid concentrations (Table 1). Insulin-stimulated
glucose disposal (mg  kg
1  min
1) was approximately
twofold lower in type 2 diabetic subjects (4.9  0.3) versus
control subjects (9.6  0.4) (P  0.0001). Basal endoge-
nous glucose production (EGP) (mg  kg
1  min
1) was
increased in type 2 diabetic patients (2.1  0.1) versus
control subjects (1.7  0.1) (P  0.002), and the basal
hepatic IRI was markedly increased in type 2 diabetic
patients versus control subjects (30.3  5.1 vs. 9.4  1.2
mg  kg
1  min
1 	 U/ml) (P  0.0001).
Plasma ceramide concentrations. Fig. 1 displays the
distribution of ceramide subspecies in the plasma of type 2
diabetic and control subjects. Consistent with previous re-
ports for patients with sepsis and atherosclerosis (23,24), the
major ceramides in plasma were C24:1 and C24:0. Type 2
diabetic subjects had increased (P  0.05–0.01) concentra-
tions (nmol/ml) of C18:0 (control, 0.26  0.03 vs. type 2
diabetes, 0.38  0.03), C20:0 (control, 0.09  0.004 vs. type
2 diabetes, 0.11  0.004), C24:1 (control, 0.43  0.03 vs. type
2 diabetes, 0.52  0.04), and total ceramide (control, 2.37 
0.19 vs. type 2 diabetes, 3.06  0.26).
Correlation between plasma ceramide subspecies
and insulin sensitivity. Spearman rank correlations
were used to determine potential relationships between
individual ceramide subspecies and insulin-stimulated glu-
cose disposal. Insulin sensitivity (mg  kg
1  min
1) was
inversely correlated with C18:0 ( 0.58, P  0.003),
C20:0 ( 0.52, P  0.008), C24:1 ( 0.51, P  0.009),
C24:0 ( 0.49, P  0.01), and total ceramide (
0.58, P  0.003) concentrations (Fig. 2).
Plasma TNF- concentration. Fasting plasma TNF-
concentration (pg/ml), a marker of inﬂammation, was
increased in type 2 diabetic subjects compared with
control subjects (control, 2.81  0.13 vs. type 2 diabetes,
4.30  0.76) (P  0.03).
Correlation between plasma ceramide subspecies
and plasma TNF- and triglyceride concentrations.
Plasma TNF- was correlated with C18:1 (0.55, P 
0.005) and C18:0 (0.47, P  0.02) ceramide subspecies
(Fig. 3). There was also a trend for ceramide subspecies
C20:0 (P  0.08) and C24:1 (P  0.06) to be correlated with
TNF- (Fig. 3). Fasting triglyceride was correlated with
C18:0 (0.48, P  0.02) and C20:0 (0.48, P  0.02)
ceramide subspecies. There was a trend for ceramide
subspecies C24:1 (P  0.07) and total ceramide (P  0.06)
to be correlated with the fasting plasma triglyceride con-
centration.
No signiﬁcant correlations were found between age,
basal EGP, fasting plasma glucose, plasma insulin, free
fatty acids, HDL, LDL, or total cholesterol concentrations
versus ceramide subspecies or total ceramide. Separate
group (control subjects and type 2 diabetic patients)
correlations were also performed between each of the
ceramide subspecies and total ceramide to age, insulin
sensitivity, plasma TNF-, and fasting triglycerides. No
additional individual group correlation was found to be
signiﬁcant (P 
 0.05).
DISCUSSION
Increased tissue (muscle and liver) and plasma fat con-
tent, i.e., lipotoxicity, plays a central role in the pathogen-
esis of type 2 diabetes (1,4,8,27,32–34). Elevated bioactive
lipids in the circulation, including lipoproteins, triglycer-
ides, and fatty acids (27), and excessive tissue lipid
deposits of long-chain fatty acyl CoAs, diacylglycerol, and
FIG. 1. Plasma concentration of ceramide subspecies in obese type 2 diabetic patients (n  13) compared with lean healthy control subjects (n 
14). Plasma concentrations were determined by quantitative tandem mass spectrometry. Data are expressed as means  SE. *P < 0.05 type 2
diabetes vs. control; Mann-Whitney unpaired test.
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of lipotoxicity. Much evidence supports a role for circu-
lating free fatty acids in the development of insulin resis-
tance, inﬂammation, and -cell dysfunction (1,3,4,33).
Recently, elevated plasma sphingolipids have been impli-
cated in the pathogenesis of obesity-induced cardiovascu-
lar and metabolic disease (37). Sphingolipid and ceramide
formation are stimulated by inﬂammatory cytokines, such
FIG. 2. Correlation of individual ceramide subspecies with the insulin-stimulated rate of glucose disposal (Rd). E, control subjects; F, type 2
diabetic patients. Spearman’s rank correlation was used to access the relationships between datasets. All correlations were signiﬁcant, P < 0.05.
FIG. 3. Correlation between individual ceramide species and plasma TNF- concentration. Spearman’s rank correlation was used to access the
relationships between datasets. E, control subjects; F, type 2 diabetic patients. TNF- correlations between C18:1 and C18:0 ceramide subspecies
were signiﬁcant, P < 0.05. TNF- correlations between C20: and C24:1 ceramide subspecies did not reach signiﬁcance but displayed a trend
toward signiﬁcance: P  0.08 and 0.06, respectively.
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in the plasma of type 2 diabetic and obese subjects (5,6).
The present study shows for the ﬁrst time that total and
speciﬁc plasma ceramide subspecies concentrations are
elevated in type 2 diabetic subjects (Fig. 1) and that these
elevated lipid moieties are associated with the severity of
insulin resistance (Fig. 2) and with elevated plasma TNF-
levels (Fig. 3). These ﬁndings suggest that elevated plasma
ceramide levels in obese type 2 diabetic subjects may be
an important mediator of insulin resistance and inﬂamma-
tion in these insulin-resistant states.
The present results are consistent with those in animals
that demonstrate increased plasma levels of sphingomye-
lin and ceramide subspecies in ob/ob mice compared with
lean controls (37). All detectable species of ceramide were
elevated in the plasma of obese mice, with the greatest
increase (86%) being observed for C18:0 ceramide (37).
Our data demonstrate that all but one ceramide subspecies
(C18:1) are elevated in obese type 2 diabetic subjects, with
C18:0 showing the greatest increase (32%) (Fig. 1). C24:0
was found to be the most abundant ceramide subspecies
in plasma, constituting 65% of the total. This is consistent
with both animal (37) and human (8,23,24) reports. From
the present and other studies (8,37), the plasma C18:0
subspecies concentration appears to be increased the
most in conditions of excess adiposity. In muscle, how-
ever, Adams et al. (8) demonstrated that the greatest
increase in ceramide subspecies in obese subjects was for
C16:0 and C20:0 (increased 76 and 83%, respectively).
Taken collectively, these observations suggest that there
may be selective regulation or formation of ceramide
species in the circulation versus tissue and that the
accumulation of ceramide in each respective compartment
may serve different biological functions and/or involve
different metabolic/inﬂammatory responses.
The etiological mechanisms responsible for the elevated
plasma ceramide levels measured in the present study
were not identiﬁed. However, one could postulate that
lipid spillover from excess fat deposits in adipocytes in the
obese type 2 diabetic subjects was a contributing source.
Ceramides also may be derived from macrophages that
have inﬁltrated adipocytes in obese and type 2 diabetic
subjects (38). Delogu et al. (39) have suggested that MNCs
produce ceramides in response to tissue inﬂammation and
hypothesized that the increased ceramide production by
MNCs may induce apoptosis in adipocytes that become
dysfunctional from chronic inﬂammation.
Tissue accumulation of ceramides in insulin-resistant
subjects has been shown to inhibit insulin action by
decreasing phosphorylation and activation of Akt (5),
whereas elevated plasma ceramide levels have been dem-
onstrated to be related to the development of atheroscle-
rosis (19,20,24). However, the role of plasma ceramide
subspecies has not been examined with regard to insulin
resistance nor have plasma ceramide subspecies been
related to the excess intracellular ceramide accumulation
in obesity and type 2 diabetes. If the elevated plasma
ceramide concentrations are the result of the spillover
phenomenon, then plasma ceramide levels may be a
marker of intracellular ceramide accumulation and thus
insulin resistance. Consistent with this scenario, we found
an inverse relationship between C18:0, C20:0, C24:1, C24:0,
and total ceramide versus whole-body insulin-stimulated
glucose disposal, as determined with the euglycemic insu-
lin clamp (Fig. 2). Although the mechanism(s) via which
individual ceramide subspecies in the circulation contrib-
ute to insulin resistance has yet to be investigated, some
insights are available from cell-permeable ceramide analog
experiments.
In C2C12 myotubes incubated with a cell-permeable
C2-ceramide analog, insulin-stimulated glucose uptake,
glycogen synthesis, and Akt serine phosphorylation were
decreased (40) in association with an increase in intracel-
lular ceramide concentration. Similar results have been
demonstrated in L6 muscle cells (41) and other cell types
(42–46) preincubated with C2- or C6-ceramide analogs.
The results of these experiments indicate that there is a
mechanism for cellular ceramide uptake. However, these
studies used short-chain ceramide analogs, whereas circu-
lating ceramides in humans and animals are of the long-
chain variety (5). It also should be noted that most
circulating ceramides and sphingolipids do not exist in a
free form but are bound to plasma proteins (47). With
regard to this, Serlie et al. (22) measured plasma and
intramuscular ceramides in response to a 6-h lipid infusion
in lean and obese subjects and found that although plasma
ceramides were signiﬁcantly increased, intramuscular cer-
amides were unchanged. These results indicate that there
is no active uptake of ceramides into the muscle (21). In
summary, it appears unlikely that plasma ceramide levels
contribute to peripheral (muscle) insulin resistance
through an uptake mechanism, and further inquiry is
required to identify the role and source of both the
elevated plasma (Fig. 1) and muscle (4) ceramide concen-
trations observed in obese and diabetic subjects. It should
be noted that, although the results of Serlie et al. (22)
demonstrated that the insulin resistance associated with
short-term lipid infusion cannot be explained by increased
muscle ceramide content, this does not exclude a role for
excessive muscle ceramide accumulation in the develop-
ment of insulin resistance in obesity and diabetes (4,7).
Chronic and acute inﬂammation have been shown to
play a role in the intracellular accumulation of ceramides
(15–17), which in turn have been implicated in the excess
production of inﬂammatory cytokines, including TNF-,
interleukin (IL)-1, and IL-6. These proinﬂammatory cyto-
kines also have been reported to be potent inducers of de
novo ceramide synthesis (5,6). Given that diabetes, obe-
sity, and other insulin-resistant states are associated with
excess production of proinﬂammatory cytokines, it is
reasonable to hypothesize that circulating ceramides may
contribute to insulin resistance through local or systemic
stimulation of the innate immune response. Consistent
with such a hypothesis, the plasma concentration of
TNF-, a marker of inﬂammation, was increased and
correlated with each plasma ceramide subspecies (Fig. 3).
TNF- stimulates ceramide formation by activating acidic
and basic SMase isoforms (48), and acute systemic inﬂam-
mation has been shown to upregulate a secretory form of
SMase, which has been linked to atherogenesis (15).
Furthermore, human vascular endothelial cells secrete
SMase on stimulation by IL-1 and interferon- (49), and
SMase is increased in the urine of patients with peritonitis,
hepatitis, and after surgery or trauma (50). These ﬁndings
are consistent with the results of Delogu et al. (39) who
found a strong correlation between MNC-derived total
ceramide concentration and plasma TNF- concentrations
in septic patients.
Study limitations. The current study was limited to those
subspecies that could be analyzed by the standards that
were commercially available at the time of investigation.
We recognize the potential importance of the ceramide
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ceramide pool in human plasma (23,24), and other cer-
amide subspecies, including C22:0, C22:1, C23:0, and C24:2
(23,24). Furthermore, the correlation between plasma
C18:1 ceramide and TNF- may not be of any physiological
or clinical relevance, because the concentration of this
ceramide was close to the lower limit of detection and
C18:1 was not found to be different between control
subjects and type 2 diabetic subjects. In addition, the
measures of plasma ceramide subspecies were obtained in
the postabsorptive state, and it should be noted that
feeding has been shown to inﬂuence plasma ceramide
levels (5,51,52). Future studies will have the opportunity to
measure additional plasma ceramide subspecies in the
postprandial condition and to quantitate simultaneously
both plasma and intracellular ceramide subspecies with
concomitant measurement of insulin sensitivity, inﬂamma-
tion, and other metabolic variables.
Conclusions. In summary, this is the ﬁrst examination of
plasma ceramide subspecies in obese subjects with type 2
diabetes. The increase in total and ceramide subspecies
concentrations correlated closely with the severity of
insulin resistance and elevated TNF- levels. The in-
creased circulating ceramide levels may be the result of
lipid spillover from skeletal muscle, liver, or adipose
tissues. Elevated plasma ceramide levels may be a marker
of insulin resistance, atherosclerotic risk, and/or obesity-
induced inﬂammation. Further study will be required to
establish mechanistic links between speciﬁc plasma cer-
amide subspecies identiﬁed herein and insulin resistance.
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